Instructions for Combitropil (Piracetam, Cinnarizine) 30 capsules
Release form
Capsules
Description:
Gelatine capsules, size №0, white;
The capsule contents are white or almost white powder.
1 cap.
Piracetam 400 mg
Cinnarizine 25 mg
Auxiliary substances:
cellulose microcrystalline,
lactose,
magnesium stearate, talc.
Gelatine capsule composition:
titanium dioxide,
methylparahydroxybenzoate,
propyl parahydroxybenzoate,
acetic acid, gelatin.
10 pcs - box-type contour (3) packages - cardboard packs.
10 pcs - packages of box contour (6) - cardboard packs.
ATC codes
N06BX Other psychostimulants and nootropic drugs Combitropil
Clinical-pharmacological groups / Group affiliation
Drug Combitropil that improves blood circulation and brain metabolism
Active substance
Piracetam
cinnarizin
Pharmacotherapy group Cinnarizine
Nootropic agent
Storage Conditions
List B. The drug Combitropil should be stored in a place inaccessible to children, dry, protected from light at a temperature not higher than 25 ° C.
Best before date
Shelf life is 2 years.
Testimony Cinnarizine:
Brain circulation disorders (arteriosclerosis of cerebral vessels, ischemic stroke, period of recovery after hemorrhagic stroke, after head injuries);
Encephalopathy of different genesis;
comatose and subcomatose states after intoxication and brain injuries;
CNS diseases accompanied by a decline in intellectual and mental functions;
labyrinthopathy of various origins (accompanied by dizziness, tinnitus, nystagmus, nausea and vomiting), Ménière syndrome;
depression;
Psychoorganic syndrome with the predominance of signs of asthma and adinamia;
asthenia of psychogenic origin;
Prevention of migraines and kinetosis;
impaired memory, thought function, and focus;
Intellectual development in children is lagging behind.
Method of use, course and dosage Cinnarizine:
The drug Combitropil should be taken inside.
Adults - 1-2 caps. 3 times/day for 1-3 months depending on the severity of the disease.
Children from 5 years old - 1-2 caps. 1-2 times/day for 1-3 months
Courses of treatment are conducted 2-3 times a year.
Chronic renal failure (CC<60 ml/min) requires a reduction in dose or an increase in the interval between the drugs Combitropil.
Application for kidney disorders
The use of the preparation in case of severe renal insufficiency is contraindicated.
Use in liver disorders
The use of the preparation in severe liver failure is contraindicated.
Terms of Sale
The drug Combitropil is prescription.
Use in children
Contraindication: Children's age (up to 5 years). Children over the age of 5 years 1-2 caps. 1-2 times/day for 1-3 months
Nosology (ICD codes)
F07
Personality and behavioural disorders caused by disease, damage or brain dysfunction
F31
Bipolar affective disorder
F32
Depressive episode
F33
Recurrent depressive disorder
F41.2
Mixed anxiety and depressive disorder
F48.0
Neurasthenia
F79
Mental retardation unspecified
G43
Migraine
G93.4
Encephalopathy unrefined
H81
Vestibular function disorders
H81.0
Ménière's disease
H81.3
Other peripheral dizziness
H93.0
Degenerative and vascular ear disease
I61
Intracerebral hemorrhage (haemorrhagic type disorder)
I63
Brain infarction
I67.2
Cerebral atherosclerosis
I69
Effects of cerebrovascular disease
S06
Intracranial injury
T90
Effects of head injuries
Drugs:
Combined drug Combitropil with a pronounced antihypoxic, nootropic and vasodilating effect.
Both components mutually potentiate their own antihypoxic effect and have a vasodilating effect. The combined drug Combitropil also contributes to a significant increase in blood flow in the brain. The toxicity of the combination does not exceed the toxicity of the individual components of the drug Combitropil.
Piracetam is a nootropic agent. It has a positive effect on the metabolic processes of the brain: increases the concentration of ATP in the brain tissue, enhances the synthesis of RNA and phospholipids, stimulates glycolytic processes, enhances glucose utilization.
Improves the integrative activity of the brain, promotes memory consolidation, facilitates the learning process.
